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Shp2 is a cytoplasmic protein-tyrosine phosphatase that is essential for normal development. Activating and
inactivating mutations have been identified in humans to cause the related Noonan and LEOPARD syndromes,
respectively. The cell biological cause of these syndromes remains to be determined. We have used the zebrafish to
assess the role of Shp2 in early development. Here, we report that morpholino-mediated knockdown of Shp2 in
zebrafish resulted in defects during gastrulation. Cell tracing experiments demonstrated that Shp2 knockdown
induced defects in convergence and extension cell movements. In situ hybridization using a panel of markers indicated
that cell fate was not affected by Shp2 knock down. The Shp2 knockdown–induced defects were rescued by active Fyn
and Yes and by active RhoA. We generated mutants of Shp2 with mutations that were identified in human patients
with Noonan or LEOPARD Syndrome and established that Noonan Shp2 was activated and LEOPARD Shp2 lacked
catalytic protein-tyrosine phosphatase activity. Expression of Noonan or LEOPARD mutant Shp2 in zebrafish embryos
induced convergence and extension cell movement defects without affecting cell fate. Moreover, these embryos
displayed craniofacial and cardiac defects, reminiscent of human symptoms. Noonan and LEOPARD mutant Shp2s were
not additive nor synergistic, consistent with the mutant Shp2s having activating and inactivating roles in the same
signaling pathway. Our results demonstrate that Shp2 is required for normal convergence and extension cell
movements during gastrulation and that Src family kinases and RhoA were downstream of Shp2. Expression of Noonan
or LEOPARD Shp2 phenocopied the craniofacial and cardiac defects of human patients. The finding that defective Shp2
signaling induced cell movement defects as early as gastrulation may have implications for the monitoring and
diagnosis of Noonan and LEOPARD syndrome.
Citation: Jopling C, van Geemen D, den Hertog J (2007) Shp2 knockdown and Noonan/LEOPARD mutant Shp2–induced gastrulation defects. PLoS Genet 3(12): e225. doi:10.
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Introduction
Shp2 (PTPN11), a nonreceptor protein-tyrosine phospha-
tase (PTP) with two Src homology 2 (SH2) domains, has a
central role in cell signaling. Shp2 is essential for embryonic
development and has a role in human disease [1]. Dominant
negative Shp2 inhibits mesoderm formation in Xenopus laevis
[2]. Gene targeting of Shp2 in Mus musculus leads to
truncation of the Shp2 protein resulting in embryonic death
around day 8.5, with a range of defects consistent with
abnormal gastrulation [3]. Chimeric mice derived from Shp2
ex3
 /  embryonic stem cells display defective morphogenetic
cell movements during gastrulation [4]. Interestingly, bona
ﬁde Shp2 null mouse embryos die peri-implantation and
Shp2 is required for trophoblast stem cell survival [5].
Activating mutations in Shp2 cause Noonan Syndrome
(NS) in humans, whereas LEOPARD syndrome (LS) is caused
by dominant negative mutations in Shp2. NS is an autosomal
dominant disorder affecting around 1 in 2,000 live births, and
is characterized by multiple defects, including short stature,
facial abnormalities, and congenital heart defects [6]. Around
50% of NS cases are caused by mutations in Shp2 [7] and 39
different mutations have been identiﬁed [8,9]. Most of the NS
mutations are localized in the N-SH2 domain or in the PTP
domain, and result in activation of Shp2 catalytic activity [10].
The mouse model for NS with an activating D61G mutation
bears striking similarities to NS patients, with defects such as
short stature, facial dysmorphism, and multiple cardiac
defects. Mice homozygous for the mutated gene die prena-
tally from severe cardiac edema and liver necrosis [11].
LS is an autosomal dominant disease characterized by
d e f e c t ss u c ha sl e n t i g i n e s ,e l e c t r o c a r d i o g r a p h i cd e f e c t s ,
ocular hypertelorism, pulmonary stenosis, abnormal genitals,
retarded growth leading to short stature, and deafness [12].
Many of the LS symptoms overlap with those seen in NS
patients, and LS is also caused by mutations in Shp2. These
mutations occur exclusively in the PTP domain of Shp2
disrupting its catalytic activity and leading to dominant
negative forms [13,14]. This leads to the conundrum of how
mutations in Shp2 with opposing effects on activity induce
syndromes in humans with similar symptoms.
Shp2 is known to be involved in many different signaling
cascades [15]. Initially, Shp2 was found to have a role in
growth factor signaling, downstream of growth factor
receptors and upstream of MAP kinase signaling. Zhang et
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activation of Src family kinases (SFKs), in that SFK activity is
reduced in the absence of Shp2, due to hyperphosphorylation
of the inhibitory phosphorylation site. Two SFKs, Fyn and
Yes, have a role in vertebrate convergence and extension (CE)
cell movements during gastrulation [17]. Moreover, the C-
terminal Src kinase, Csk, a negative regulator of SFKs, is
crucial for normal gastrulation cell movements as well [18].
Morpholino (MO)-mediated Fyn/Yes knockdown in zebraﬁsh
embryos phenocopies Silberblick/Wnt11 and Pipetail/Wnt5
morphants both morphologically and molecularly. Although
Fyn and Yes act in a synergistic manner with Wnt5 and
Wnt11, they do not function in a linear pathway; instead, they
operate in parallel, converging downstream on the small
GTPase RhoA. Given the role of Fyn and Yes in gastrulation
cell movements, the function of Shp2 as an indirect activator
of SFKs, and evidence from Xenopus and mouse that Shp2 may
have a role in gastrulation cell movements, we hypothesized
that Shp2 is involved in CE cell movements during
gastrulation.
Here, we show that MO-mediated knockdown of Shp2 in
zebraﬁsh embryos resulted in defective CE cell movements
during gastrulation, but not cell speciﬁcation. Genetic
epistasis analyses indicated that Shp2 acts through Fyn and
Yes, upstream of the small GTPase RhoA. Expression of
mutant NS- or LS-Shp2 in zebraﬁsh embryos resulted in
overlapping phenotypes, in that normal gastrulation was
impaired without affecting cell speciﬁcation. Speciﬁcally, we
found that NS-Shp2 induced CE cell movement defects.
Moreover, craniofacial and cardiac development were also
impaired. The NS- and LS-Shp2s did not act synergistically
upon coinjection, which is consistent with the two mutants
acting in the same signaling pathway with opposing effects.
The defects resulting from expression of mutant Shp2s
correspond to symptoms in human NS/LS patients. The
notion that defective Shp2 signaling induced cell movement
defects as early as gastrulation is important and may
have implications for the monitoring and diagnosis of NS
and LS.
Results/Discussion
Shp2 Knockdown Induced Defects in CE during
Gastrulation
Zebraﬁsh Shp2 (Ensembl database ENSDARG00000020334,
http://www.ensembl.org) is highly homologous to human and
mouse Shp2 (91.2% and 90.3% protein sequence identity,
respectively) (Figure 1A). In situ hybridization experiments
show that shp2 is ubiquitously expressed during early
zebraﬁsh development (Figure 1B–1F). At 24 h post
fertilization (hpf) and 3 d post fertilization (dpf), shp2 was
broadly expressed, with enhanced levels of expression in the
anterior parts of the embryo (Figure 1G and 1H). We
designed a Shp2-MO targeting the start codon and injected
it at the one-cell stage. We found that 1ng Shp2-MO
consistently produced speciﬁc defects in embryonic develop-
ment. The ﬁrst visible defect is a failure of the embryo to
extend properly around the yolk at 10 hpf (Figure 2A–2C).
At later stages (4 dpf), embryos were shorter and developed a
hammerhead phenotype similar to Wnt5 morphants (Figure
2D–2F). Alcian blue staining of 4 dpf embryos indicated that
the cartilaginous structures in the head of Shp2 and Wnt5
morphants reside more posteriorly than in uninjected
controls; compare Meckel’s cartilage (black asterisk) and
the ceratohyal (red asterisk) (Figure 2G–2I). We quantiﬁed
the hammerhead phenotype by assessment of the ratio of the
distance to the tip of the nose divided by the distance
between the eyes (as illustrated in Figure S1). There was a
signiﬁcant difference in this ratio between wild-type (WT)
Figure 1. Zebrafish Shp2 Is Conserved and Is Expressed Ubiquitously
during Development
(A) Schematic representation of zebrafish Shp2 with two SH2 domains to
the N-terminal side of the PTP domain. The overall sequence identity
with human and mouse Shp2 is indicated. (B–F) In situ hybridization with
a Shp2-specific antisense probe at various stages of development: (B) 8-
cell stage, (C) 4 hpf, (D) shield stage, (E) 10 hpf, (F) 14 somite (14 s, 14
hpf), (G) 24 hpf, and (H) 3 dpf.
doi:10.1371/journal.pgen.0030225.g001
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Author Summary
Shp2 is a protein-tyrosine phosphatase and mutations in Shp2 cause
the related Noonan and LEOPARD syndromes in humans. We used
the zebrafish to investigate the cell biological role of Shp2 in early
development. Shp2 knockdown and expression of mutant Shp2 that
contained mutations corresponding to those found in human
Noonan and LEOPARD patients, induced similar convergence and
extension cell movement defects during gastrulation without
affecting cell specification. Active Src family kinases and active
RhoA rescued the Shp2 knockdown, indicating that signaling
downstream of Shp2 was mediated by Src family kinases and RhoA.
Expression of the Noonan and LEOPARD Shp2s in zebrafish induced
craniofacial and cardiac defects that were reminiscent of the
symptoms observed in human patients. Coinjections demonstrated
that Noonan and LEOPARD Shp2s did not cooperate, which is
consistent with the two mutants acting in the same signaling
pathway with opposing effects. The finding that defective Shp2
signaling induced cell movement defects as early as gastrulation
may have important implications for the monitoring and diagnosis
of Noonan and LEOPARD syndromes in humans.(1.87 6 0.03, n ¼ 4) and Shp2-MO injected (1.40 6 0.20, n ¼
10) embryos (p , 0.001, student’s t-test), demonstrating that
there was a signiﬁcant craniofacial defect following Shp2
knockdown. Coinjection of 300 pg human shp2 RNA rescued
all Shp2-MO-induced defects (Figure 2J). Higher amounts of
Shp2-MO induced more severe defects (unpublished data),
but not all defects were rescued by coinjection of synthetic
RNA. Therefore, we used 1 ng Shp2-MO for all subsequent
knockdowns.
Reduced extension of the body axis upon Shp2 knockdown
is consistent with CE cell movement defects. Therefore, we
directly investigated whether Shp2 knockdown affected CE
cell movements by cell tracing. Caged ﬂuorescein was (co-)
injected at the one-cell stage. At 6 hpf, a cluster of cells within
the dorsal shield was labeled by uncaging the caged
ﬂuorescein with a short, localized pulse of UV light. This
group of cells was monitored every 2 h during gastrulation.
The distance the cells migrated is directly proportional to
embryonic extension. Repeating the process at 908 to the
shield gives an effective measurement of convergence of the
Figure 2. Shp2-MO–Induced CE Cell Movement Defects
Zebrafish embryos were not injected (A, D, G) or microinjected with Wnt5-MO (5 ng) (B, E, H) or Shp2-MO (1.0 ng) (C, F, I) at the one-cell stage.
(A–C) Morphology at 10 hpf shows reduced anterior extension of the Wnt5-MO– and Shp2-MO–injected embryos. Arrowheads indicate the anterior of
the embryos
(D–F) Morphology of the Wnt5 and Shp2 knockdown embryos at 4 dpf show a mild hammerhead-like phenotype.
(G–I) Alcian blue staining of the cartilage in the heads of 4 dpf embryos. Black asterisk, Meckel’s cartilage; red asterisk, ceratohyal. (J) Zebrafish embryos
were (co-) injected with Shp2-MO (1.0 ng) and 300 pg human shp2 mRNA and scored at 4 dpf.
(K,L) Embryos were loaded with caged fluorescein dextran and the fluorophore was uncaged at the shield stage (6 hpf) dorsally to determine anterior
extension (K, white arrow in inset; site of uncaging, black arrowhead) or laterally to determine dorsal migration (L, white arrow in inset; initial position at
the shield stage, black arrowhead). Cell labeling of the same embryos was followed immediately after uncaging at 80% epiboly (8 hpf) and at tailbud
stage (10–10.5 hpf). WT and Shp2-MO–injected embryos were assessed and averages for ten embryos are given in degrees.
doi:10.1371/journal.pgen.0030225.g002
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Shp2 and Gastrulation Cell Movementsmesendodermal cells. Shp2 knockdown resulted in a signiﬁ-
cant reduction in CE during gastrulation (Figure 2K,L). These
results demonstrate that Shp2 knockdown induced defects in
CE cell movements during gastrulation.
Shp2 Knockdown Did Not Affect Cell Specification
Shp2 is known to be involved in many different signaling
cascades [15]. In fact, in a recent study in Drosophila, over 40
different genes associated with at least four separate path-
ways (EGFR, Notch, DPP, and Jak/Stat) were found to interact
with gain-of-function Shp2 mutants [19]. Some of these
pathways are important for proper cell speciﬁcation and
defective signaling leads to a variety of phenotypes, including
defects in the A-P axis. We used a panel of well-characterized
in-situ markers that have been used before to assess effects
on cell speciﬁcation [20–23]. Bone morphogenetic protein 2b
(bmp2b) is involved in the speciﬁcation of ventral cell fates
but was not affected by knockdown of Shp2 (Figure 3A and
3B). Expression of the dorsalizing factor chordin (chd)
remained the same (Figure 3C and 3D), as did the dorsal
speciﬁc gene goosecoid (gsc), which is expressed in the
organizer (Figure 3E and 3F). Expression of the mesendo-
dermal marker notail (ntl) also remained unchanged in Shp2
morphants (Figure 3G and 3H). These markers indicate that
knockdown of Shp2 did not alter cell fate in early zebraﬁsh
embryos, suggesting it has a role in CE cell movements,
rather than cell speciﬁcation.
Expression of the anterior brain markers, six3 (forebrain),
pax2 (mid-hindbrain boundary), and krox20 (rhombomeres 3
and 5) persisted in the Shp2 morphants, indicating that the
structures these markers delineate were present. However,
the expression patterns of these three genes were shifted
posteriorly (Figure 3Il–Ll), which—in the case of pax2 and
six3—was accompanied by a broader expression pattern
(Figure 3Ka–La). At 8 hpf, cyclops (cyc) is expressed in axial
mesendodermal cells of gastrulating embryos. Shp2 mor-
phants clearly have a shorter expression pattern when
compared to uninjected controls (Figure 3O and 3P). These
results are consistent with disrupted convergence and
extension cell movements upon knockdown of Shp2.
Shp2 might regulate CE cell movements by modulation of
expression of the noncanonical Wnts, or by Fyn and Yes,
known regulators of CE cell movements. However, the
expression of wnt11, wnt5, fyn, and yes remained unaffected
in Shp2-MO injected embryos (Figure 3Q–3X), indicating that
Shp2 has a more direct role in CE signaling.
Shp2 Acts through Fyn,Yes, and RhoA in Gastrulation Cell
Movements
In order to assess the mechanism underlying Shp2-
mediated cell movements in gastrulation, we coinjected
MOs with synthetic mRNAs and assessed CE cell movement
defects by measurement of the angle between the most
anterior and the most posterior tissues at 10 hpf. The Shp2-
MO by itself induced an increase in the angle between the
extremes of the developing embryo, which was rescued by
coinjection of synthetic human shp2 mRNA (Table 1).
Figure 3. Shp2 Knockdown Did Not Affect Cell Specification
Control and Shp2-MO–injected embryos were fixed at 6 hpf (A–H, Q–X),
8 hpf (O,P), or 10 hpf (I–L), and in situ hybridization was done with the
indicated probes. Either lateral views (A–D, Il–Ll, M, N, S, T, W, X) or
animal pole views (E–H, Ia-La, O–R, U, V) are depicted here.
doi:10.1371/journal.pgen.0030225.g003
Table 1. Shp2 and Fyn/Yes Signal in Parallel to Wnt5,
Converging on RhoA
RNA Shp2-MO Fyn/Yes-MO Wnt5-MO
  96 6 1 (57) 99 6 1 (28) ND
shp2 89 6 2 (22) 100 6 2 (21) 100 6 1 (20)
fyn/yes 91 6 1 (26) 88 6 1 (30) ND
rhoA 90 6 1 (24) 93 6 1 (28) ND
wnt5 97 6 2 (24) ND ND
MOs and synthetic RNAs were coinjected as indicated at the one-cell stage and the angle
between the anterior- and posterior-most extensions of the embryos was determined at
10 hpf. At least 20 embryos were analyzed for each injection. The angles are given in
degrees 6 standard error of the mean with the number of embryos analyzed in
parentheses. The average angle in WT non-injected control embryos is 87 6 1 (30).
ND, not determined.
doi:10.1371/journal.pgen.0030225.t001
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Shp2 and Gastrulation Cell MovementsCoinjection of RNA encoding constitutively active Fyn and
Yes with Shp2-MO also rescued the Shp2 morphants (Table
1), indicating that Fyn and Yes are genetically downstream of
Shp2. Fyn- and Yes-MOs induced severe reductions in
embryo body axis extension, and coinjection with synthetic
shp2 mRNA did not rescue (Table 1), conﬁrming that Shp2 is
upstream of Fyn and Yes. Low amounts of Shp2-MO together
with Wnt5-MO, which did not induce defects when coinjected
alone, induced a hammerhead phenotype at 4 dpf (Figure S2),
indicating that Shp2 and Wnt5 interact genetically. However,
Wnt5 mRNA did not rescue the Shp2 morphants and shp2
mRNA did not rescue Wnt5 morphants (Table 1), indicating
that Shp2 and Wnt5 do not operate in the same linear genetic
pathway. Active RhoA rescued the Shp2 morphants (Table 1),
which is consistent with Shp2 being upstream of Fyn and Yes,
which, in turn, act upstream of RhoA.
Shp2 is most commonly associated with the Ras/MAPK
pathway, which regulates many developmental processes,
such as cell proliferation and cell speciﬁcation [24,25].
However, the phenotype we observed in the Shp2 knockdown
embryos was not consistent with a massive reduction in cell
proliferation, nor with changes in cell speciﬁcation (Figure 3).
Given that the Shp2 knockdown phenotype was rescued by
coinjection of active RhoA, the Ras/MAPK signaling pathway
appeared not to be essential for Shp2 signaling during
gastrulation. Instead, we implicate SFKs and RhoA down-
stream in the Shp2 signaling cascade. In Xenopus laevis,
mutant, active Shp2 induces elongation of animal cap
explants, which is blocked by coexpression of dominant
negative RhoA [26], suggesting involvement of RhoA rather
than Ras/MAPK, similar to what we observed in early
zebraﬁsh embryos. In a recent report, Shp2 knockdown was
reported to induce craniofacial hypoplasia and heart mal-
formations, similar to Raf1 knockdown [27]. Mutations in
Raf1 were linked to NS [27,28]. Other Ras/MAPK signaling
components were identiﬁed in NS as well, including KRAS
and SOS1 [29–31]. Although we cannot exclude that Ras/
MAPK signaling has a role in Shp2 signaling in gastrulation
cell movements, we demonstrate here that we can rescue the
Shp2 knockdown phenotype with active SFKs or active RhoA,
indicating that SFKs and RhoA are downstream of Shp2 in
gastrulation cell movements.
Noonan and LEOPARD Syndrome Shp2-Induced CE Cell
Movement Defects
To investigate the use of zebraﬁsh as a model for NS and
LS, we generated two NS-Shp2 and two LS-Shp2 mutants by
introducing mutations into zebraﬁsh Shp2, as found in NS
and LS patients, respectively (Figure 4A). For NS, we
substituted Asp61 with Gly (D61G) or Thr73 with Ile (T73I).
For LS, Ala462 was mutated to Thr (A462T), or Gly465 to Ala
(G465A). The two NS proteins showed a 6-fold increase in
activity compared to WT Shp2 in in vitro PTP assays, whereas
the two LS-Shp2s did not exhibit detectable PTP activity
(Figure 4B). These results are consistent with catalytic activity
data of mammalian NS and LS Shp2 mutants [10,14].
To determine how mutant Shp2 affects the development of
zebraﬁsh, we injected synthetic RNA encoding NS-Shp2 or
LS-Shp2 into embryos at the one-cell stage. We titrated the
amount of RNA down to amounts that reproducibly induced
speciﬁc phenotypes (D61G, 150pg; T73I, 100pg; A462T, 75pg;
and G465A, 50pg). These phenotypes were not observed in
embryos injected with green ﬂuorescent protein (GFP) RNA
(300pg). Similar amounts of RNA encoding WT Shp2 (150–
300 pg) did not induce defects. Very high amounts of WT
Shp2 RNA (.800 pg) induced phenotypes, similar to NS- and
LS-Shp2, albeit the phenotypes were not as severe (unpub-
lished data), indicating that NS- and LS-Shp2 had strong,
dominant functions. Injection of NS- or LS-Shp2s resulted in
signiﬁcantly shorter embryos at 4 dpf when compared to
noninjected or GFP-injected controls (Figure 4C and 4D).
Body axis extension was already reduced at 10 hpf as the
angle between the most anterior and posterior tissues was
signiﬁcantly increased upon injection of each of the NS- and
LS-Shp2s (Figure 4E). Cell tracing experiments demonstrated
that both extension (Figure 4F) and convergence (Figure 4G)
were reduced signiﬁcantly upon injection of mutant T73I NS-
Shp2. In situ hybridization with ntl and gsc markers on NS-
and LS-injected embryos demonstrated that cell speciﬁcation
was not affected (Figure S3). These results demonstrate that
expression of NS-Shp2 induced defective CE cell movements
during gastrulation without affecting cell speciﬁcation.
NS- and LS-Shp2–Induced Defects Resembled Symptoms
in NS and LS Patients
Embryos injected with either NS- or LS-Shp2 RNA
developed craniofacial abnormalities that were apparent at
4 dpf. Notably the eyes were set wider apart and anterior
structures had not extended normally (Figure 5A–5D). Alcian
blue stainings of cartilaginous structures showed that
structures, including Meckel’s cartilage (black asterisk) and
the ceratohyal (red asterisk), resided more posteriorly than in
WT controls. Failure of anterior structures to extend
normally and wider spacing of the eyes in NS- or LS-Shp2
expressing zebraﬁsh embryos was similar to the Shp2 knock-
down zebraﬁsh embryos (Figure 2). Moreover, the facial
abnormalities in NS- and LS-Shp2 expressing zebraﬁsh were
reminiscent of the symptoms that are observed in NS/LS
patients and the NS mouse model. There is no evidence to
suggest that this phenotype was caused by defective gastru-
lation cell movements. Mutants with disrupted gastrulation
such as wnt5 [32] and knypek [33] develop similar craniofacial
anomalies. Rescue of the knypek mutant by RNA injection led
to rescue of the gastrulation defects, but not of the
craniofacial defects, indicating that these defects are inde-
pendent [33].
Injection of NS- or LS-Shp2 RNA caused defects in heart
development. Similar defects were observed upon injection
of NS- or LS-Shp2, and the defects varied in penetrance from
mild to grossly edematous, as illustrated for NS-Shp2 (Figure
5E–5H). In situ hybridization using the heart-speciﬁc probe
cmlc2 at 24 hpf demonstrates that the heart of NS/LS-injected
embryos failed to jog to the left in approximately 30% of the
NS- or LS-Shp2–injected embryos (Figure 5I–5K). Homozy-
gous NS mutant mice develop a grossly edematous heart [11],
similar to NS and LS zebraﬁsh, indicating that the injected
zebraﬁsh phenocopy the symptoms observed in human
patients and in gene-targeted mice.
The CE cell movement defects that we observed are most
likely resulting from defective directional cell movements,
which in turn result from impaired cell polarization. We
hypothesize that the craniofacial and cardiac defects we
observed may also result from defective cell movements of
neural crest cells shaping the face and myocardial cells
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Shp2 and Gastrulation Cell MovementsFigure 4. NS and LS Mutant Shp2 Expression Induced CE Cell Movement Defects during Gastrulation
(A) Schematic representation of zebrafish Shp2 with the NS and LS mutations indicated.
(B) PTP activity of WT Shp2, NS (D61G and T73I) and LS (A462T and G465A) mutant Shp2 was assayed using p-nitrophenylphosphate and quantified
spectrophotometrically. Each experiment was done with three different amounts of GST-fusion protein (black bar, high; grey bar, middle; and white bar,
low).
(C) NS- and LS-Shp2 expression reduced zebrafish embryo body length. Three injected embryos (D61G, 150pg) at 4 dpf are depicted with a noninjected
control embryo at the bottom. The figure is representative of defects associated with all NS- and LS-Shp2 expressing embryos.
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Shp2 and Gastrulation Cell Movementsshaping the heart, respectively. Future work should focus
on the role of Shp2 in polarization and migration of these
cells.
NS- and LS-Shp2 Do Not Cooperate
Finally, we investigated how activating and inactivating
mutations in Shp2 might produce similar phenotypes in early
zebraﬁsh development. To this end, we coinjected suboptimal
amounts of combinations of either NS-Shp2, LS-Shp2, or
GFP, which did not induce phenotypes by themselves, and
embryos were assessed at 4 dpf. Coinjection of the two NS-
Shp2s (D61G and T73I) resulted in a signiﬁcant increase in
the observed phenotypes compared to coinjection of D61G or
T73I with GFP (Figure 6). Likewise, coinjection of the two LS-
Shp2s (A462T and G465A) induced an increase in phenotypes
as compared to control A462T or G465A coinjections with
GFP. In contrast, coinjection of suboptimal amounts of
combinations of NS-Shp2 RNA with LS-Shp2 RNA did not
lead to a signiﬁcant increase in the number of affected
embryos (Figure 6). These results demonstrate that combina-
tions of NS-Shp2 and LS-Shp2 do not act synergistically,
whereas suboptimal amounts of NS-Shp2 mutants or LS-Shp2
mutants cooperate to induce defects in zebraﬁsh embryos.
The observation that activation and inhibition of the same
signaling pathway induces similar phenotypes is not unpre-
cedented. Microinjection of RNA encoding Rok2 or Gal-
pha12/13 induces similar gastrulation defects as knockdown
of Rok2 or Galpha12/13, respectively [21,22]. An activity
window exists for these factors. If overall activity falls outside
of this window, the resulting phenotypes are very similar. We
established that coinjection of two different NS-Shp2s or LS-
Shp2s led to an increase in the number of affected embryos.
Our results are consistent with NS-Shp2 and LS-Shp2 acting
in the same pathway, with one activating and the other
inhibiting signaling.
Conclusion
We show here that knockdown of Shp2 induced CE cell
movement defects, but did not affect cell speciﬁcation. These
defects were rescued by active Fyn and Yes and active RhoA,
indicating that SFK-Rho signaling, rather than MAPK signal-
ing was required for this function of Shp2. Expression of NS-
or LS-mutant Shp2 RNA in zebraﬁsh embryos led to
overlapping phenotypes, characterized by craniofacial and
cardiac defects, reminiscent of the symptoms observed in NS/
LS patients. The notion that defective Shp2 signaling induced
cell movement defects as early as gastrulation is important
and may have implications for the monitoring and diagnosis
of NS and LS.
(D) The length of the embryos was measured at 4 dpf and the average is shown here. Two tailed student t-tests indicate a significant decrease in length
after injection of each NS or LS RNA ( p , 0.001).
(E) NS- and LS-Shp2 RNA injection results in reduced extension of the body axis at 10 hpf. The angle between the most anterior and posterior
embryonic structure (arrowheads in inset) was determined at the one-somite stage and the average angle is depicted here in degrees. Two tailed
student t-tests indicate a significant increase in the angle after injection of NS or LS RNA (p , 0.001). The number of embryos used here is indicated (n).
(F, G) Cell tracing was done as described in Figure 2. NS-Shp2 (T73I) was coinjected with caged fluorophore at the one-cell stage and after uncaging at 6
hpf, extension and convergence were determined at 8 hpf and 10 hpf in ten embryos per condition.
doi:10.1371/journal.pgen.0030225.g004
Figure 5. Craniofacial and Heart Defects upon NS or LS RNA Injection
(A,C) Extension of anterior structures (black asterisk) was impaired and the eyes were spaced wider apart (black bar) in NS-Shp2–injected embryos
(D61G, 150 pg) (C) than in the noninjected control (A). The figure is representative of defects associated with all NS- and LS-Shp2–injected embryos.
(B,D) Alcian blue staining of the cartilage in the head of NS-Shp2 injected embryos (D) compared to noninjected control (B). Black asterisk, Meckel’s
cartilage; red asterisk, ceratohyal. (E–K) NS- and LS-induced heart defects. (E–H) Morphology of representative 3 dpf embryos with (E) noninjected
control, (F) mild, (G) intermediate, and (H) severe heart defect. Phenotypes evoked by NS- and LS-Shp2 were indistinguishable. (I–K) cmlc2 in situ
hybridization marks the heart. (I) Noninjected control with normal heart jogging (red asterisk). (J) Injected embryo showing defective cardiac jogging
(red asterisk). (K) Quantification of heart jogging of NS- or LS-Shp2 RNA–injected embryos stained with cmlc2, depicted as percent non-jogging.
doi:10.1371/journal.pgen.0030225.g005
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Shp2 and Gastrulation Cell MovementsMaterials and Methods
Zebraﬁsh and in situ hybridization. Zebraﬁsh were kept and the
embryos were staged as described before [34]. In situ hybridizations
were done essentially as described [35] using probes speciﬁc for bmp2b
[36], chd [37], cmcl2 [38], cyc [39], gsc [40], krox20 [41], ntl [42], pax2 [43],
six3 [44], wnt5 [45], wnt11, fyn, and yes [18].
Constructs. The mutations D61G, T73I, A462T and G465A were
introduced into zebraﬁsh Shp2 by site-directed mutagenesis and
cloned into EcoR1/BamH1 sites of pBSK11 and veriﬁed by sequenc-
ing. Fusion proteins were expressed from pGEX-based bacterial
vectors encoding GST fusion proteins of WT Shp2 and all four NS/LS
mutated constructs. Fusion proteins were produced in bacteria and
puriﬁed using standard procedures.
MOs, RNA, and injections. Antisense MOs were designed to
include the start ATG of the respective cDNAs and ordered from
GeneTools (Philomath): Shp2, 59-GGTGGAACCACCTTCGGGATGT-
CAT. The Fyn, Yes, and Wnt5 MOs were described previously [17]. 59
capped sense RNAs were synthesized using the mMessage mMachine
kit (Ambion). The amount of RNA that was injected at the one-cell
stage was optimized for each synthetic RNA. For the rescue
experiments, we used mutant, constitutively active Fyn and Yes,
derived by mutagenesis of their C-terminal inhibitory tyrosine
phosphorylation sites to phenylalanine. Wnt5 and active RhoAV12
were described previously [17]. The NS- and LS-Shp2 RNAs contained
their respective mutations, D61G, T73I, A462T, or G465A. Pheno-
types were assessed at the indicated stages.
Cell tracing. Embryos were (co-) injected at the one-cell stage with
0.25% 4,5-dimethoxy-2-nitrobenzyl (DMNB)-caged ﬂuorescein dex-
tran (10,000 MW, Molecular Probes). Uncaging was done as described
[17] at shield stage (6 hpf) using an Axioplan microscope, equipped
with a UV light source, adjustable pinhole, and 403objective. Pictures
were taken immediately following uncaging, at 80% epiboly (8 hpf)
and tailbud stage (10 hpf). The angles for dorsal convergence and
anterior extension were determined using NIH imaging software.
Phosphatase assays. Puriﬁed GST-fusion proteins were directly
incubated in PTP assay buffer (20 mM MES buffer pH 6.0, 1 mM
EDTA, 150 mM NaCl, 1 mM dithiotreitol, and 10 mM p-nitro-
phenylphosphate) for 45 min at 30 8C. The reactions were quenched
with 0.4 M NaOH, and optical density was measured with a
spectrophotometer at 415 nm (wavelength).
Supporting Information
Figure S1. Morphometry of the Hammerhead Phenotype
The distance between the eyes and the distance from the middle of
the eyes to the tip of the nose (as indicated in the left panel) was
determined in 4 dpf embryos after staining with alcian blue (see
Materials and Methods). The ratio of the distance to the tip of the
nose and the distance between the eyes was determined and is plotted
in the bar graph, depicted in the panel on the right. Four WT and ten
Shp2-MO injected embryos were analyzed. There is a signiﬁcant
difference in ratios between the WT (1.87 6 0.03) and Shp2
knockdown (1.40 6 0.20), indicating that Shp2 knockdown indeed
induced a hammerhead phenotype.
Found at doi:10.1371/journal.pgen.0030225.sg001 (323 KB PPT).
Figure S2. Shp2 and Wnt5 Knockdown Acts Synergistically to Induce
a Hammerhead Phenotype at 4 dpf
Shp2-MO and Wnt5-MO were injected at 50% of their normal
concentration. By themselves, these injections did not induce defects
(compare to morphology at 4 dpf with WT, noninjected control).
Coinjection of Shp2-MO and Wnt5-MO did induce the hammerhead
phenotype at 4 dpf. Note the blunted face and the increased distance
between the eyes in the double-injected embryo (Shp2 þ Wnt5).
Found at doi:10.1371/journal.pgen.0030225.sg002 (583 KB PPT).
Figure S3. Expression of NS- and LS-Shp2 Did Not Induce Defects in
Cell Speciﬁcation
Synthetic RNA encoding NS-Shp2 (D61G or T73I) or LS-Shp2 (A462T
or G465A) was injected into one-cell stage zebraﬁsh embryos. The
embryos were ﬁxed at 6 hpf and in situ hybridization was done with
the indicated probes. Animal pole views are depicted here.
Expression of the mesendodermal marker ntl and of the organiser
marker gsc remained unchanged in the NS- and LS-Shp2–expressing
embryos.
Found at doi:10.1371/journal.pgen.0030225.sg003 (208 KB PPT).
Accession Numbers
The National Center for Biotechnology Information (NCBI) Entrez
database (http://www.ncbi.nlm.nih.gov/sites/gquery?itool¼toolbar) ac-
cession numbers of the genes and proteins used in this study are: Fyn
(Danio rerio), EMBL AJ620748; RhoA (Homo sapiens), swissprot P61586;
Shp2 (Danio rerio), NCBI NM_199846; Shp2 (Homo sapiens),
swissprot Q06124; Wnt5a (Mus musculus), swissprot P22725; and Yes
(Danio rerio), EMBL AJ620749.
Identiﬁers of the human Noonan and LEOPARD syndromes are
OMIM 163950 and OMIM 151100, respectively.
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